3rd quarter earnings for endo pharmaceuticals

Third-quarter 2023 Generic Pharmaceuticals segment revenues were $134 million, a decrease of 33% compared to $201 million during third-quarter 2022. This change was primarily attributable to decreased VASOSTRICT ® revenues due to lower price resulting from generic competition. Third-quarter 2023 Sterile Injectables segment revenues were $95 million, a decrease of 20% compared to $119 million during third-quarter 2022. Third-quarter 2023 XIAFLEX ® revenues were $113 million, a 9% increase compared to third-quarter 2022 driven by increased net selling price and increased volumes.Įstablished Products revenues decreased 7% to $53 million in third-quarter 2023 compared to $57 million in third-quarter 2022 due primarily to product discontinuations.

This change was primarily due to an increase in XIAFLEX ® and Other Specialty revenues, partially offset by a decrease in SUPPRELIN ® LA revenues mainly driven by lower average net selling price as a result of business mix and lower overall market volumes. Specialty Products revenues increased 3% to $150 million in third-quarter 2023 compared to $146 million in third-quarter 2022. Third-quarter 2023 Branded Pharmaceuticals segment revenues were $203 million compared to $204 million during third-quarter 2022. This change was primarily driven by lower interest and adjusted operating expenses which were partially offset by decreased revenues. This change was primarily due to lower litigation-related and asset impairment charges and lower interest expense as a result of the August 2022 Chapter 11 filing.Īdjusted income from continuing operations in third-quarter 2023 was $131 million compared to $112 million in third-quarter 2022. Reported loss from continuing operations in third-quarter 2023 was $28 million compared to reported loss from continuing operations of $718 million in third-quarter 2022. This decrease was primarily attributable to decreased revenues from the Generic Pharmaceuticals and Sterile Injectables segments. Total revenues were $452 million in third-quarter 2023, a decrease of 17% compared to $542 million in third-quarter 2022. Refer to note (13) in the 'Notes to the Reconciliations of GAAP and Non-GAAP Financial Measures' section below for additional discussion. Refer to the 'Supplemental Financial Information' section below for reconciliations of certain non-GAAP financial measures to the most directly comparable GAAP financial measures.Įffective January 1, 2022, these non-GAAP financial measures now include acquired in-process research and development charges which were previously excluded under Endo's legacy non-GAAP policy.

The information presented in the table above includes non-GAAP financial measures such as Adjusted Income from Continuing Operations, Adjusted Diluted Weighted Average Shares, Adjusted Diluted Net Income per Share from Continuing Operations and Adjusted EBITDA. In the case of Adjusted Diluted Weighted Average Shares, Adjusted Income from Continuing Operations is used in determining whether to include such dilutive impact. Reported Diluted Net Loss per Share from Continuing Operations is computed based on weighted average shares outstanding and, if there is income from continuing operations during the period, the dilutive impact of ordinary share equivalents outstanding during the period. 6, 2023 /PRNewswire/ - Endo International plc (OTC: ENDPQ) today reported financial results for the third-quarter ended September 30, 2023. ENDO REPORTS THIRD-QUARTER 2023 FINANCIAL RESULTSĭUBLIN, Nov.

3rd quarter earnings for endo pharmaceuticals